Abstract:After completion of this article, the reader should be able to recall that paroxysmal nocturnal hemoglobinuria (PNH) during pregnancy increases adverse events for both the mother and the fetus, state that maternal and fetal mortality are both high, and explain that the major complications occur in the postpartum period.
“…Another possible explanation for the high rate of caesarian deliveries is the PNH-related smooth muscle dystonia that may compromise the progress of labor in PNH patients. Fetal mortality was 4%, which is lower than the 7.2% reported by Fieni et al 4 In our study, newborn birth weight was generally low, though overall outcome was favorable for these children.…”
Section: Discussioncontrasting
confidence: 53%
“…Thromboses occurred in patients who received anticoagulation as well as in patients who did not, confirming that prophylactic antithrombotic therapy is not always sufficient to prevent thromboembolism in PNH patients. 24 In comparison with previous reports, 4,28 we recorded a high incidence of premature delivery and caesarian section. A planned and therapeutically induced delivery was preferred in the vast majority of cases to improve management of the patient during this particularly risky period.…”
Section: Discussionmentioning
confidence: 49%
“…[25][26] Among 43 pregnancies reported in the medical literature between 1965 and 2006, 8 were associated with thrombosis. Two incidents of thrombosis occurred during pregnancy 5,19 and the remaining 6 occurred during the postpartum period, 4,7,19,[21][22]27 leading to maternal death in 3 cases. 19,21,27 In our series, we recorded no thrombotic events during pregnancy, possibly because most (64%) of our patients received antithrombotic prophylaxis.…”
Section: Discussionmentioning
confidence: 99%
“…To date, fewer than 30 reports [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] have been published, comprising case reports or small series of no more than 7 patients. Fieni et al 4 reviewed obstetric literature about pregnancy and PNH published between 1965 and 2005. They assessed 43 cumulative cases which revealed maternal and fetal mortality rates of 11.6% and 7.2%, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…Although there is little information about PNH and pregnancy in the literature, a recent review identified 23 clinical reports published between 1965 and 2005 describing pregnancy outcomes in 43 women with PNH. 4 Maternal and fetal mortality rates were 11.6% and 7.2%, respectively. Venous thrombotic events (VTEs) were the major cause of maternal death.…”
The online version of this article has a Supplementary Appendix.
BackgroundPregnancy in women with paroxysmal nocturnal hemoglobinuria is rare, with few reports on maternal and fetal mortality rates.
Design and MethodsA specific questionnaire designed to solicit data on pregnancies in women with paroxysmal nocturnal hemoglobinuria was sent to all members of the French Society of Hematology in January 2008.
ResultsWe identified 27 pregnancies in 22 women at 10 French Society of Hematology centers between 1978 and 2008. The median age was 21.5 years at diagnosis of paroxysmal nocturnal hemoglobinuria and 27 years at pregnancy. None of these women had received eculizumab during their pregnancy. Maternal complications, consisting mostly of cytopenias requiring transfusions, occurred in 95% of cases. Two cases of severe aplastic anemia (de novo in one case and relapse in the other) were recorded. No thrombotic events occurred during pregnancy, whereas 4 postpartum thromboses (16%) were recorded, 2 of which were fatal (maternal mortality rate 8%). Most patients received antithrombotic prophylaxis during pregnancy and postpartum (n=16; 64%). Delivery was preterm in 29% of cases, and birth weight was less than 3 kg in 53% of cases. Fetal mortality rate was 4%.
ConclusionsPregnancy during paroxysmal nocturnal hemoglobinuria is associated with increased maternal and fetal mortality rates (8% and 4%, respectively, in this series). Maternal mortality is related to postpartum thromboses. Prophylactic anticoagulation is recommended during pregnancy and for six weeks postpartum.
“…Another possible explanation for the high rate of caesarian deliveries is the PNH-related smooth muscle dystonia that may compromise the progress of labor in PNH patients. Fetal mortality was 4%, which is lower than the 7.2% reported by Fieni et al 4 In our study, newborn birth weight was generally low, though overall outcome was favorable for these children.…”
Section: Discussioncontrasting
confidence: 53%
“…Thromboses occurred in patients who received anticoagulation as well as in patients who did not, confirming that prophylactic antithrombotic therapy is not always sufficient to prevent thromboembolism in PNH patients. 24 In comparison with previous reports, 4,28 we recorded a high incidence of premature delivery and caesarian section. A planned and therapeutically induced delivery was preferred in the vast majority of cases to improve management of the patient during this particularly risky period.…”
Section: Discussionmentioning
confidence: 49%
“…[25][26] Among 43 pregnancies reported in the medical literature between 1965 and 2006, 8 were associated with thrombosis. Two incidents of thrombosis occurred during pregnancy 5,19 and the remaining 6 occurred during the postpartum period, 4,7,19,[21][22]27 leading to maternal death in 3 cases. 19,21,27 In our series, we recorded no thrombotic events during pregnancy, possibly because most (64%) of our patients received antithrombotic prophylaxis.…”
Section: Discussionmentioning
confidence: 99%
“…To date, fewer than 30 reports [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] have been published, comprising case reports or small series of no more than 7 patients. Fieni et al 4 reviewed obstetric literature about pregnancy and PNH published between 1965 and 2005. They assessed 43 cumulative cases which revealed maternal and fetal mortality rates of 11.6% and 7.2%, respectively.…”
Section: Discussionmentioning
confidence: 99%
“…Although there is little information about PNH and pregnancy in the literature, a recent review identified 23 clinical reports published between 1965 and 2005 describing pregnancy outcomes in 43 women with PNH. 4 Maternal and fetal mortality rates were 11.6% and 7.2%, respectively. Venous thrombotic events (VTEs) were the major cause of maternal death.…”
The online version of this article has a Supplementary Appendix.
BackgroundPregnancy in women with paroxysmal nocturnal hemoglobinuria is rare, with few reports on maternal and fetal mortality rates.
Design and MethodsA specific questionnaire designed to solicit data on pregnancies in women with paroxysmal nocturnal hemoglobinuria was sent to all members of the French Society of Hematology in January 2008.
ResultsWe identified 27 pregnancies in 22 women at 10 French Society of Hematology centers between 1978 and 2008. The median age was 21.5 years at diagnosis of paroxysmal nocturnal hemoglobinuria and 27 years at pregnancy. None of these women had received eculizumab during their pregnancy. Maternal complications, consisting mostly of cytopenias requiring transfusions, occurred in 95% of cases. Two cases of severe aplastic anemia (de novo in one case and relapse in the other) were recorded. No thrombotic events occurred during pregnancy, whereas 4 postpartum thromboses (16%) were recorded, 2 of which were fatal (maternal mortality rate 8%). Most patients received antithrombotic prophylaxis during pregnancy and postpartum (n=16; 64%). Delivery was preterm in 29% of cases, and birth weight was less than 3 kg in 53% of cases. Fetal mortality rate was 4%.
ConclusionsPregnancy during paroxysmal nocturnal hemoglobinuria is associated with increased maternal and fetal mortality rates (8% and 4%, respectively, in this series). Maternal mortality is related to postpartum thromboses. Prophylactic anticoagulation is recommended during pregnancy and for six weeks postpartum.
Key Clinical MessageParoxysmal nocturnal hemoglobinuria (PNH) results from reduced complement regulatory proteins on hematopoietic cells, predisposing patients to intravascular hemolysis, thrombophilia, and cytopenias. Women diagnosed in pregnancy can experience significant maternofetal complications. Trials of eculizumab in PNH excluded pregnant women. Here, we report the first Canadian patient taken through pregnancy on eculizumab.
Key Clinical MessageEculizumab is highly effective in inhibiting complement activation and has successfully shown to prevent complications and to improve quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH). Its application during pregnancy showed favorable fetal and maternal outcome in the presented case and has proven to be effective without raising safety concerns.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.